Close Menu

NEW YORK – Shares of Illumina have fallen 9 percent from the Wednesday market open and 23 percent from the intraday high on rumors the sequencing giant will acquire liquid biopsy firm Grail.

Following a short rise to an intraday high of $366.01, Illumina's share price fell to $320.70 in afternoon trading on the Nasdaq.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.